Background: Ivacaftor exhibits anti-staphylococcal properties but does not clear from the lungs of people with cystic fibrosis (pwCF). We assessed whether exposure to therapeutic concentrations of ivacaftor could allow to form small colony variants (SCVs), a phenotype commonly associated with bacterial persistence.
Methods: Humanized G551D-CFTR (hG551D) rats were treated with ivacaftor for 7 days.
Background: Significant insomnia symptoms can have important impacts on the health and quality of life of caregivers of persons with cognitive decline (PwCD).
Objective: To characterize the prevalence of clinically significant insomnia symptoms using the recommended community cutoff for the Insomnia Severity Index (ISI; ≥10) and identify correlates of the presence of symptoms.
Methods: Eighty PwCD caregivers were recruited from a memory and aging care clinic in an academic medical center and completed all study procedures (M = 66.